
    
      This study planned to evaluate 2 cohorts: Cohort 1, up to 8 participants to receive IV doses
      of ALXN1830 (SYNT001 Dose 1); Cohort 2, up to 12 participants to receive IV doses of ALXN1830
      (SYNT001 Dose 2).

      This study was terminated after the safety, tolerability, pharmacokinetics, pharmacodynamics,
      and efficacy were characterized in participants with WAIHA in Cohort 1 (SYNT001 Dose 1),
      before any participants were enrolled in Cohort 2.
    
  